IDH1R132H mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Wang, Xiao Wei ^a,b,c   Labussière, Marianne ^a,b,c   Valable, Samuel ^d,e,f   Pérès, Elodie A ^d,e,f   Guillamo, Jean Sébastien ^d,e,f,g   Bernaudin, Myriam ^d,e,f   Sanson, Marc ^a,b,c,h  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d GIP CYCERON   (France)

^e UNIVERSITÉ DE CAEN   (France)

^f SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ARTICLE; CANCER RADIOTHERAPY; CELL HYPOXIA; CELL PROLIFERATION ASSAY; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CODON; COLONY FORMATION; CONTROLLED STUDY; GENE MUTATION; GLIOBLASTOMA CELL LINE; GLIOMA CELL; HUMAN; HUMAN CELL; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; AMINO ACID SUBSTITUTION; BRAIN NEOPLASMS; CELL PROLIFERATION; DRUG SCREENING; ENZYMOLOGY; GENETIC TRANSDUCTION; GENETICS; GLIOMA; MUTATION; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; REPRODUCIBILITY; TIME; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; RADIATION TOLERANCE; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR STEM CELL ASSAY;

EID: 84901800906     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/198697     Document Type: Article

References (17)

1. Parsons D. W., Jones S., Zhang X., Lin J. C.-H., Leary R. J., Angenendt P., Mankoo P., Carter H., Siu I.-M., Gallia G. L., Olivi A., McLendon R., Rasheed B. A., Keir S., Nikolskaya T., Nikolsky Y., Busam D. A., Tekleab H., Diaz L. A. Jr., Hartigan J., Smith D. R., Strausberg R. L., Marie S. K. N., Shinjo S. M. O., Yan H., Riggins G. J., Bigner D. D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W., An integrated genomic analysis of human glioblastoma multiforme. Science 2008 321 5897 1807 1812 2-s2.0-52949127312 10.1126/science.1164382
2. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., Hallani S. E., Boisselier B., Mokhtari K., Hoang-Xuan K., Delattre J.-Y., Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of Clinical Oncology 2009 27 25 4150 4154 2-s2.0-70249097408 10.1200/JCO.2009.21.9832
3. Van Den Bent M. J., Dubbink H. J., Marie Y., Brandes A. A., Taphoorn M. J. B., Wesseling P., Frenay M., Tijssen C. C., Lacombe D., Idbaih A., Van Marion R., Kros J. M., Dinjens W. N. M., Gorlia T., Sanson M., IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research 2010 16 5 1597 1604 2-s2.0-77649122144 10.1158/1078-0432.CCR-09-2902
4. Houillier C., Wang X., Kaloshi G., Mokhtari K., Guillevin R., Laffaire J., Paris S., Boisselier B., Idbaih A., Laigle-Donadey F., Hoang-Xuan K., Sanson M., Delattre J.-Y., IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010 75 17 1560 1566 2-s2.0-78149249554 10.1212/WNL.0b013e3181f96282
5. van den Bent M. J., Brandes A. A., Taphoorn M. J. B., Adjuvant PCV chemotherapy in newly diagnosed anaplastic oligodendroglioma-long term follow-up of EORTC Brain Tumor Group study 26951. Journal of Clinical Oncology 2013 31 3 344 350 10.1200/JCO.2012.43.2229
6. Cairncross J. G., Wang M., Jenkins R. B., Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology 2014 32 8 783 790 10.1200/JCO.2013.49.3726
7. Dang L., White D. W., Gross S., Bennett B. D., Bittinger M. A., Driggers E. M., Fantin V. R., Jang H. G., Jin S., Keenan M. C., Marks K. M., Prins R. M., Ward P. S., Yen K. E., Liau L. M., Rabinowitz J. D., Cantley L. C., Thompson C. B., Vander Heiden M. G., Su S. M., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009 462 7274 739 744 2-s2.0-72049125350 10.1038/nature08617
8. Lu C., Ward P. S., Kapoor G. S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C. R., Khanin R., Figueroa M. E., Melnick A., Wellen K. E., Oĝrourke D. M., Berger S. L., Chan T. A., Levine R. L., Mellinghoff I. K., Thompson C. B., IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012 483 7390 474 478 2-s2.0-84858796262 10.1038/nature10860
9. Turcan S., Rohle D., Goenka A., Walsh L. A., Fang F., Yilmaz E., Campos C., Fabius A. W. M., Lu C., Ward P. S., Thompson C. B., Kaufman A., Guryanova O., Levine R., Heguy A., Viale A., Morris L. G. T., Huse J. T., Mellinghoff I. K., Chan T. A., IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012 483 7390 479 483 2-s2.0-84858796263 10.1038/nature10866
10. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.-H., Ito S., Yang C., Wang P., Xiao M.-T., Liu L.-X., Jiang W.-Q., Liu J., Zhang J.-Y., Wang B., Frye S., Zhang Y., Xu Y.-H., Lei Q.-Y., Guan K.-L., Zhao S.-M., Xiong Y., Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α -ketoglutarate-dependent dioxygenases. Cancer Cell 2011 19 1 17 30 2-s2.0-78651463452 10.1016/j.ccr.2010.12.014
11. Koivunen P., Lee S., Duncan C. G., Lopez G., Lu G., Ramkissoon S., Losman J. A., Joensuu P., Bergmann U., Gross S., Travins J., Weiss S., Looper R., Ligon K. L., Verhaak R. G. W., Yan H., Kaelin W. G. Jr., Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012 483 7390 484 488 2-s2.0-84858798104 10.1038/nature10898
12. Bralten L. B. C., Kloosterhof N. K., Balvers R., Sacchetti A., Lapre L., Lamfers M., Leenstra S., De Jonge H., Kros J. M., Jansen E. E. W., Struys E. A., Jakobs C., Salomons G. S., Diks S. H., Peppelenbosch M., Kremer A., Hoogenraad C. C., Sillevis Smitt P. A. E., French P. J., IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Annals of Neurology 2011 69 3 455 463 2-s2.0-79953287708 10.1002/ana.22390
13. Jin H. L., Sung Y. K., In S. K., Park J.-W., Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. Journal of Biological Chemistry 2007 282 18 13385 13394 2-s2.0-34250308841 10.1074/jbc.M700303200 (Pubitemid 47100548)
14. Shi J., Zuo H., Ni L., An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation. Neurological Sciences. In press
15. Mohrenz I. V., Antonietti P., Pusch S., Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 2013 18 1416 1425 10.1007/s10495-013-0877-8
16. Li S., Chou A. P., Chen W., Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncology 2013 15 57 68 10.1093/neuonc/nos261
17. Zhao S., Lin Y., Xu W., Jiang W., Zhai Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K.-L., Xiong Y., Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 α Science 2009 324 5924 261 265 2-s2.0-64849098267 10.1126/science.1170944